Literature DB >> 23104584

In vitro antifungal drug susceptibilities of Penicillium marneffei from China.

Donghua Liu1, Ling Liang, Jimin Chen.   

Abstract

Penicillium marneffei infections in immunocompromised patients are often fatal, but early treatment with appropriate antifungal agents may have a good prognosis. To select drugs for treating P. marneffei infection in Southern China, the susceptibilities of antifungal agents against P. marneffei isolates were evaluated. Twenty-five strains of P. marneffei were isolated from patients from 2008 to 2010 in Guangxi Province of China, and 14 strains were isolated from bamboo rats. The activity of voriconazole, fluconazole, itraconazole, terbinafine, and amphotericin B on the isolates was assessed by MIC analysis. Voriconazole MIC against strains of P. marneffei ranged from 0.004 to 0.25 mg/l, and it had the lowest MIC (geometric mean values, 0.04 mg/l) in comparison to the other antifungal agents. The MICs of other antifungal agents, in order of lowest to highest, were as follows: itraconazole, terbinafine, amphotericin B, and fluconazole. The results show voriconazole and itraconazole are active against P. marneffei isolates in vitro, and terbinafine may have unrealized usefulness in the treatment of infections caused by this yeast form.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104584     DOI: 10.1007/s10156-012-0511-7

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  12 in total

Review 1.  Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

Authors:  Cunwei Cao; Liyan Xi; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2019-12       Impact factor: 2.574

2.  Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.

Authors:  H-L Lei; L-H Li; W-S Chen; W-N Song; Y He; F-Y Hu; X-J Chen; W-P Cai; X-P Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-13       Impact factor: 3.267

3.  Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study.

Authors:  Yanyin Ouyang; Shuangqi Cai; Hao Liang; Cunwei Cao
Journal:  Mycopathologia       Date:  2017-01-20       Impact factor: 2.574

4.  In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.

Authors:  Susanna K P Lau; George C S Lo; Clare S K Lam; Wang-Ngai Chow; Antonio H Y Ngan; Alan K L Wu; Dominic N C Tsang; Cindy W S Tse; Tak-Lun Que; Bone S F Tang; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study.

Authors:  Weie Huang; Tiantian Li; Changjing Zhou; Fanglin Wei; Cunwei Cao; Jianning Jiang
Journal:  Mycopathologia       Date:  2021-02-22       Impact factor: 2.574

Review 6.  Dimorphic fungal osteoarticular infections.

Authors:  B Rammaert; M N Gamaletsou; V Zeller; C Elie; R Prinapori; S J Taj-Aldeen; E Roilides; D P Kontoyiannis; B Brause; N V Sipsas; T J Walsh; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

7.  Caenorhabditis elegans: a simple nematode infection model for Penicillium marneffei.

Authors:  Xiaowen Huang; Dedong Li; Liyan Xi; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

8.  T. marneffei infection complications in an HIV-negative patient with pre-existing pulmonary sarcoidosis: a rare case report.

Authors:  Xiaoming Yu; Keji Miao; Changsheng Zhou; Yuelin Cai; Xiaoying Huang; Yanfan Chen; Mayun Chen; Hui Cai; Lin Zhang
Journal:  BMC Infect Dis       Date:  2018-08-10       Impact factor: 3.090

9.  Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.

Authors:  Katharine E Stott; Thuy Le; Thu Nguyen; Sarah Whalley; Jennifer Unsworth; Vo Trieu Ly; Ruwanthi Kolamunnage-Dona; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

10.  Comparison of Talaromyces marneffei Infection in Human Immunodeficiency Virus-positive and Human Immunodeficiency Virus-negative Patients from Fujian, China.

Authors:  Hong-Ru Li; Shao-Xi Cai; Yu-Sheng Chen; Mei-E Yu; Neng-Luan Xu; Bao-Song Xie; Ming Lin; Xin-Lan Hu
Journal:  Chin Med J (Engl)       Date:  2016-05-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.